The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparative analysis of second and subsequent chemotherapy lines on short- and long-term survival of elderly Medicare metastatic colon cancer patients.
Nader Hanna
Research Funding - Bayer
Ebere Onukwugha
Consultant or Advisory Role - Janssen Pharmaceutical
Research Funding - Bayer; Novartis; Pfizer; Sanofi
Kaloyan A Bikov
Research Funding - Bayer
Zhiyuan Zheng
No relevant relationships to disclose
Brian S. Seal
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
C. Daniel Mullins
Consultant or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Eisai; Genentech; GlaxoSmithKline; Janssen Pharmaceutical ; Mitsubishi Tanabe Pharma; Novartis; Pfizer; Sanofi
Honoraria - Bayer
Research Funding - Bayer; Pfizer; Sanofi